Darbepoetin Alfa is Erythropoietin
analogue. This molecule was tested in diabetics with chronic Kidney disease and
anemia in TREAT trail, there was no benefit of Darbepoetin Alfa on death, CV events,
CV death, or renal events. Present trail i.e.
RED-HF also reestablishes no benfit Darbepoetin in patient’s heart
failure and anemia.
RED-HF trial was started in year 2006 and results reported
in jan-2013. RED-HF trial included 2278 patients with anemia and left
ventricular systolic dysfunction. These patients were randomized to Darbepoetin
Alfa or placebo, the main aim of treatment group was to achieve HB% of
13grm/dl. Primary end point was composite death due to any cause or worsening of
heart failure and readmission. There was no benfit by Darbepoetin alpha versus
placebo (hazard ratio 1.01, 95% CI 0.90-1.13).
Darbepoetin increases the risk of stroke without
clinical benfit. Still FDA has approved usage of Darbepoetin in chronic kidney
disease with anemia
Labels: For Doctors, Heart Failure, Intermediate Level